BEL 20 drops 1.87% as Brussels session ends
Published on 11/17/2026 at 18:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBroad losses weigh on Brussels
- The BEL 20 fell 1.87% at Tuesday's close in Brussels.
- Healthcare, financial and technology stocks led the decline.
- D'Ieteren was the strongest performer, while UCB, Elia and argenx posted the steepest losses.
The BEL 20 fell 1.87% at the close of Tuesday's Brussels session, with losses concentrated in healthcare, financials and technology. The market summary was published by Investing.com in a Reuters-sourced report dated November 17, 2026.
Healthcare and financials lead losses
Declining stocks outnumbered advancing shares on the Brussels Stock Exchange by 72 to 22, while 13 stocks finished unchanged. The breadth of the move points to broad participation in the index's decline rather than weakness confined to a single constituent.
D'Ieteren outperforms as UCB retreats
D'Ieteren gained 0.17% to close at 174.90, making it the best performer among the constituents highlighted in the market summary. Solvay finished unchanged at 24.80, while Sofina slipped 0.75% to 265.60.
UCB was the weakest of the named constituents, falling 2.81% to 286.80. Elia declined 2.67% to 131.00 and argenx lost 2.64% to 854.40.
